Our study is a preliminary evaluation of the efficacy of neoadjuvant anti-HER-2 therapy and chemotherapy in Chinese patients with HER-2-positive breast cancer, and more studies are needed to comprehensively evaluate the prognosis of patients. Here, ERBB2 is linked to breast carcinoma.